Latest Cardiac Power News
Aug 12, 2016
Verify here. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: firstname.lastname@example.org. All rights reserved. All other trademarks recognized. Copyright © 1997-2016 BioPortfolio Limited. Site developed by Alacrify Ltd .
Cardiac Power Frequently Asked Questions (FAQ)
Where is Cardiac Power's headquarters?
Cardiac Power's headquarters is located at Cincinnati.
What is Cardiac Power's latest funding round?
Cardiac Power's latest funding round is Series A.
How much did Cardiac Power raise?
Cardiac Power raised a total of $600K.
Who are the investors of Cardiac Power?
Investors of Cardiac Power include Health Foundation of Greater Cincinnati, Queen City Angels, Blue Chip Venture Company and BIOSTART.
Who are Cardiac Power's competitors?
Competitors of Cardiac Power include Avertix, NeoChord, Ancora Heart, Respicardia, CardioKinetix and 7 more.
Compare Cardiac Power to Competitors
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
Cardiac Dimensions is a company focused on improving the treatment of heart failure in the healthcare sector. The company offers a non-surgical device, designed to treat patients with mitral valve insufficiency, which works with the natural structure and function of the heart to treat the condition and related symptoms. The company primarily sells to the healthcare industry. It was founded in 2000 and is based in Kirkland, Washington.
JenaValve is a global medical device company focused on the healthcare sector, specifically in the domain of structural heart disease. The company's main offering is the development of innovative medical device technology, particularly transcatheter aortic valve replacement (TAVR) systems, designed to treat patients suffering from aortic valve disease. JenaValve primarily serves the healthcare industry, with a specific focus on cardiac care. It was founded in 2006 and is based in Irvine, California.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.